| abstract |
Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: Δ 12 -prostaglandin J 3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. Δ 12 -prostaglandin J 3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs. |